title: 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia.
abstract: Forty one patients with hairy cell leukemia (HCL) were treated with 2-chloro-deoxyadenosine (2-CdA) administered in various schedules. Complete remission (CR) was achieved in 31 (76%) patients and partial remission (PR) in 9 (22%). The mean duration of remission (CR + PR) was 25.2 months (range 9-45 months). One patient did not respond to therapy. Twelve out of 16 patients (75%) achieved CR after 5-day intravenous infusions of 2-CdA and 19 out of 25 patients (76%) after 7-day courses. In 19 out of 23 patients (82.6%) CR was achieved after intermittent 2-hour infusions and in 12 out of 18 (66.7%) after continuous 24-hour infusion. The differences were not statistically significant. Side effects of 2-CdA were similar in both groups except for infections, which were less frequently observed in the group treated for 5 days. The results of our study suggest that 2-CdA can be effectively administered to patients with HCL using 5-day courses and a 2-hour daily infusion.
authors.affiliation: 2nd Department of Internal Medicine, Medical University of Lódź, Poland.
authors.forename: T
authors.initials: T
authors.lastname: Robak
authors.forename: M
authors.initials: M
authors.lastname: Błasińska-Morawiec
authors.forename: E
authors.initials: E
authors.lastname: Krykowski
authors.forename: J
authors.initials: J
authors.lastname: Hansz
authors.forename: M
authors.initials: M
authors.lastname: Komarnicki
authors.forename: M
authors.initials: M
authors.lastname: Kazimierczak
authors.forename: L
authors.initials: L
authors.lastname: Konopka
authors.forename: S
authors.initials: S
authors.lastname: Maj
authors.forename: A
authors.initials: A
authors.lastname: Hellmann
authors.forename: J M
authors.initials: JM
authors.lastname: Zaucha
authors.forename: L
authors.initials: L
authors.lastname: Urasiński
authors.forename: B
authors.initials: B
authors.lastname: Zdziarska
authors.forename: S
authors.initials: S
authors.lastname: Kotlarek-Haus
authors.forename: L
authors.initials: L
authors.lastname: Usnarska-Zubkiewicz
authors.forename: Z
authors.initials: Z
authors.lastname: Kuratowska
authors.forename: J
authors.initials: J
authors.lastname: Dwilewicz-Trojaczek
authors.forename: J
authors.initials: J
authors.lastname: Hołowiecki
authors.forename: M
authors.initials: M
authors.lastname: Krawczyk-Kulis
authors.forename: P
authors.initials: P
authors.lastname: Grieb
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017338:Cladribine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007239:Infections / Q000453:epidemiology; D007262:Infusions, Intravenous; D016898:Interferon-alpha / Q000627:therapeutic use; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013156:Splenectomy; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D007155:Immunologic Factors; D016898:Interferon-alpha; D017338:Cladribine